| __timestamp | Iovance Biotherapeutics, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2704597 | 100244000 |
| Thursday, January 1, 2015 | 15470000 | 29674000 |
| Friday, January 1, 2016 | 28037000 | 14917000 |
| Sunday, January 1, 2017 | 71615000 | 14118000 |
| Monday, January 1, 2018 | 99828000 | 8737000 |
| Tuesday, January 1, 2019 | 166023000 | 6900000 |
| Wednesday, January 1, 2020 | 201727000 | 6248000 |
| Friday, January 1, 2021 | 259039000 | 12312000 |
| Saturday, January 1, 2022 | 294781000 | 19721000 |
| Sunday, January 1, 2023 | 344077000 | 31283000 |
Infusing magic into the data realm
In the competitive world of biotechnology, innovation is the key to success. Over the past decade, Iovance Biotherapeutics, Inc. and MannKind Corporation have taken distinct paths in their investment strategies. Iovance has consistently increased its research and development (R&D) spending, growing from a modest 2.7 million in 2014 to a staggering 344 million by 2023. This represents an impressive growth of over 12,600% in R&D investment, underscoring their commitment to pioneering new therapies.
In contrast, MannKind Corporation's R&D expenses have fluctuated, peaking at 100 million in 2014 and then stabilizing around 31 million by 2023. This indicates a more conservative approach, focusing on optimizing existing technologies. As the biotech landscape evolves, these investment strategies will play a crucial role in shaping the future of these companies and their contributions to medical advancements.
Who Prioritizes Innovation? R&D Spending Compared for Amgen Inc. and Iovance Biotherapeutics, Inc.
R&D Insights: How BeiGene, Ltd. and MannKind Corporation Allocate Funds
R&D Insights: How Pharming Group N.V. and MannKind Corporation Allocate Funds
Grifols, S.A. or Iovance Biotherapeutics, Inc.: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Ionis Pharmaceuticals, Inc. and MannKind Corporation
Research and Development Expenses Breakdown: Opthea Limited vs MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Amneal Pharmaceuticals, Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Ultragenyx Pharmaceutical Inc. and MannKind Corporation
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Iovance Biotherapeutics, Inc.
R&D Spending Showdown: Catalyst Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Protagonist Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Analyzing R&D Budgets: MannKind Corporation vs BioCryst Pharmaceuticals, Inc.